Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accumulated Expenses: 2014-2024

Historic Accumulated Expenses for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $6.1 million.

  • Zevra Therapeutics' Accumulated Expenses fell 42.59% to $6.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.1 million, marking a year-over-year decrease of 42.59%. This contributed to the annual value of $6.1 million for FY2024, which is 42.59% down from last year.
  • Zevra Therapeutics' Accumulated Expenses amounted to $6.1 million in FY2024, which was down 42.59% from $10.7 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Accumulated Expenses registered a high of $10.7 million during FY2023, and its lowest value of $1.1 million during FY2021.
  • In the last 3 years, Zevra Therapeutics' Accumulated Expenses had a median value of $6.1 million in 2024 and averaged $6.2 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Accumulated Expenses spiked by 537.84% in 2023, and later slumped by 42.59% in 2024.
  • Zevra Therapeutics' Accumulated Expenses (Yearly) stood at $1.3 million in 2020, then dropped by 18.86% to $1.1 million in 2021, then skyrocketed by 58.73% to $1.7 million in 2022, then surged by 537.84% to $10.7 million in 2023, then plummeted by 42.59% to $6.1 million in 2024.